Key result
Circular RNAs regulate cardiovascular disease mechanisms and show promise as stable circulating biomarkers.
Why the study?
Identification of novel therapeutic targets and biomarkers for cardiovascular diseases is urgently needed due to their status as the largest contributor to mortality worldwide.
Circular RNAs show potential as novel therapeutic targets and biomarkers for cardiovascular diseases, though functional and clinical studies are currently limited.
circRNAs may serve as CVD biomarkers or targets; leaves open prospective validation before clinical use.
Cardiovascular diseases (CVDs) represent the largest contributor to mortality worldwide. Identification of novel therapeutic targets and biomarkers for CVDs is urgently needed. Circular RNAs (circRNAs) are endogenous, abundant, and stable non-coding RNAs formed by back-splicing events. Their role as regulators of gene expression has been increasingly reported. Notably, circRNAs mediate essential physiological and pathological processes in the cardiovascular system. Our first aim, therefore, is to summarize recent advances in the role of circRNAs in cardiac development as well as in pathogenesis of various CVDs. Because circRNAs are stable in circulation and their dynamic changes may reflect different disease stages, they are considered ideal biomarkers. Therefore, our second aim is to review studies that have identified circulating circRNAs as biomarkers for CVDs. Finally, we discuss the shortage of functional studies and the limitations of available clinical studies and provide future perspectives.
No takes yet. Share an insight, caveat, or question.
Bei et al. (2018) conducted a review in Cardiovascular diseases. Circular RNAs (circRNAs) was evaluated. Circular RNAs mediate essential physiological and pathological processes in the cardiovascular system and show potential as stable circulating biomarkers for cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: